Places Focus on Subject Identification and Operational Planning

CINCINNATI, OH – Radiant Research, Inc. today announced that it is actively recruiting
subjects and establishing operational plans for upcoming H1N1 vaccine trials. The
World Health Organization declared the H1N1 influenza outbreak a pandemic, and the
CDC has shipped virus samples to several manufacturers with the hope of having
vaccine available to the general public by the fall. Manufacturers will need to complete
clinical trials prior to release of vaccine to the public.

“Our research sites are ideal for this type of clinical trial,” said Julie McHugh, Vice
President of Late Phase Clinical Research, Radiant Research, Inc. “We have conducted
over 200 vaccine trials and enrolled thousands of subjects into these trials in the past
five years. We know how to enroll these trials quickly and efficiently, and we enforce the
standards that ensure quality data collection.”

“We have over a million subjects in our database and they are both familiar with the
research process and very interested in this type of trial,” said Michael Kritschgau, Vice
President of Radiant Recruitment. “We are currently making contact with these potential
subjects so we can be ready to enroll once the manufacturers are ready to move to the
clinical trials stage. We anticipate that companies producing the vaccine will soon be
reaching out to various research facilities; we will be ready when we get that call.”

About Radiant Research, Inc.

Based in Cincinnati, Ohio, Radiant Research, Inc. (radiantresearch.com) is a
comprehensive clinical research company offering study conduct, development and
centralized patient recruitment services to the biopharmaceutical and medical device
industry. Radiant is comprised of 24 wholly-owned premier clinical research centers, a
full service CRO and a centralized patient recruitment company, employing over 400
clinical research professionals. Radiant has conducted more than 8,500 clinical trials
across 18 therapeutic specialties.

###